Littérature scientifique sur le sujet « NEUROBLASTOMA, HIF-2α »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « NEUROBLASTOMA, HIF-2α ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "NEUROBLASTOMA, HIF-2α"
Pini, Nicola, Zihe Huo, Urs Kym, Stefan Holland-Cunz et Stephanie J. Gros. « AQP1-Driven Migration Is Independent of Other Known Adverse Factors but Requires a Hypoxic Undifferentiated Cell Profile in Neuroblastoma ». Children 8, no 1 (15 janvier 2021) : 48. http://dx.doi.org/10.3390/children8010048.
Texte intégralHolmquist-Mengelbier, Linda, Erik Fredlund, Tobias Löfstedt, Rosa Noguera, Samuel Navarro, Helén Nilsson, Alexander Pietras et al. « Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma : HIF-2α promotes an aggressive phenotype ». Cancer Cell 10, no 5 (novembre 2006) : 413–23. http://dx.doi.org/10.1016/j.ccr.2006.08.026.
Texte intégralMontalto, Angela Simona, Monica Currò, Tiziana Russo, Nadia Ferlazzo, Daniela Caccamo, Riccardo Ientile, Carmelo Romeo et Pietro Impellizzeri. « CO2 Pneumoperitoneum Effects on Molecular Markers of Tumor Invasiveness in SH-SY5Y Neuroblastoma Cells ». European Journal of Pediatric Surgery 30, no 06 (10 novembre 2019) : 524–28. http://dx.doi.org/10.1055/s-0039-1700547.
Texte intégralCimmino, F., M. Avitabile, L. Pezone, G. Scalia, D. Montanaro, M. Andreozzi, L. Terracciano, A. Iolascon et M. Capasso. « CD55 is a HIF-2α marker with anti-adhesive and pro-invading properties in neuroblastoma ». Oncogenesis 5, no 4 (avril 2016) : e212-e212. http://dx.doi.org/10.1038/oncsis.2016.20.
Texte intégralNilsson, Helén, Annika Jögi, Siv Beckman, Adrian L. Harris, Lorenz Poellinger et Sven Påhlman. « HIF-2α expression in human fetal paraganglia and neuroblastoma : relation to sympathetic differentiation, glucose deficiency, and hypoxia ». Experimental Cell Research 303, no 2 (février 2005) : 447–56. http://dx.doi.org/10.1016/j.yexcr.2004.10.003.
Texte intégralNilsson, M. B., P. E. Zage, L. Zeng, L. Xu, T. Cascone, H. K. Wu, B. Saigal, P. A. Zweidler-McKay et J. V. Heymach. « Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma : implications for antiangiogenic mechanisms of multikinase inhibitors ». Oncogene 29, no 20 (8 mars 2010) : 2938–49. http://dx.doi.org/10.1038/onc.2010.60.
Texte intégralHamidian, Arash, Kristoffer von Stedingk, Matilda Munksgaard Thorén, Sofie Mohlin et Sven Påhlman. « Differential regulation of HIF-1α and HIF-2α in neuroblastoma : Estrogen-related receptor alpha (ERRα) regulates HIF2A transcription and correlates to poor outcome ». Biochemical and Biophysical Research Communications 461, no 3 (juin 2015) : 560–67. http://dx.doi.org/10.1016/j.bbrc.2015.04.083.
Texte intégralHafizi, Redona, Faik Imeri, Roland H. Wenger et Andrea Huwiler. « S1P Stimulates Erythropoietin Production in Mouse Renal Interstitial Fibroblasts by S1P1 and S1P3 Receptor Activation and HIF-2α Stabilization ». International Journal of Molecular Sciences 22, no 17 (31 août 2021) : 9467. http://dx.doi.org/10.3390/ijms22179467.
Texte intégralPietras, A., D. Gisselsson, I. Øra, R. Noguera, S. Beckman, S. Navarro et S. Påhlman. « High levels of HIF-2α highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche ». Journal of Pathology 214, no 4 (11 décembre 2007) : 482–88. http://dx.doi.org/10.1002/path.2304.
Texte intégralChen, Shu-jen, Nicholas E. Hoffman, Santhanam Shanmughapriya, Lei Bao, Kerry Keefer, Kathleen Conrad, Salim Merali et al. « A Splice Variant of the Human Ion Channel TRPM2 Modulates Neuroblastoma Tumor Growth through Hypoxia-inducible Factor (HIF)-1/2α ». Journal of Biological Chemistry 289, no 52 (12 novembre 2014) : 36284–302. http://dx.doi.org/10.1074/jbc.m114.620922.
Texte intégralThèses sur le sujet "NEUROBLASTOMA, HIF-2α"
PEZONE, Lucia. « Cellular proteome alterations in response to hypoxia inducible factor HIF-2α in normoxic neuroblastoma cells ». Doctoral thesis, 2016. http://hdl.handle.net/11562/938441.
Texte intégralNeuroblastoma (NB) is an embryonal tumor of neuroectodermal cells derived from precursor or immature cells of the sympathetic nervous system (SNS). This disease rappresents the most common extracranial tumor in infants, accounting for 8% to 10% of all childhood cancer and for approximately 15% of cancer deaths in children. The deep knowledge of NB biology is imperative toward the development of novel therapy. Hypoxia is a typical feature of several solid tumors microenvironment and is associated with a poor prognosis and resistance to therapy. The relationship among hypoxia, tumor phenotypes and clinical parameters in NB is not well characterized. Tumor adaptation to hypoxia is mainly mediated by two transcription factors: the hypoxia-inducible factors (HIFs) HIF-1α and HIF-2α. HIF-2α is stable also in normoxia condition and continues to be active even after 48–72 h of hypoxia in some neuroblastoma cell lines thus indicate that HIF-2α plays a critical role in driving the hypoxic response. Interesting, HIF-2α is correlated with poor patient prognosis in NB and is localizated in tumor peri-vascular niches. These findings indicate that HIF-2α protein expression in NB samples at normoxic levels might affect the aggressive tumor phenotype. The main aim of my phD program has been to get new insights into the molecular mechanism of tumor aggressiveness mediated by HIF-2α protein overexpression in NB cells. Interesting, HIF-2α overexpressing cells acquire an undifferentiated phenotype and the ability to grow as neurospheres in soft agar. Then I applied two different proteomic approaches, DIGE analysis and FACS detection of membrane antigens to identify new putative prognostic and therapeutic hypoxia-related targets to be used in clinical treatment of aggressive NB forms. The identified proteins have important roles in a variety of pathways such as “citrate cycle”, “glycolysis” and “splicesoma” thus indicating that HIF-2α over-expression affects the cellular metabolic balance and increases the processes of mRNA regulation. These findings might provide an innovative therapeutic strategy by combining anti-metabolic drugs and pathways inhibitors.Among the cell surface antigens which were differentialy HIF-2α regulated CD55 was the most significantly expressed marker in our cellular system. I assessed CD55 has anti-adhesive and pro-invading functions that might provide the basis for NB solid tumors to survive as microscopic residual disease. Furthermore, the use of CD55 antibody-based visualization as in PET (Positron Emission Tomography) imaging will have implications for the development of more accurate diagnosis and prognosis in challenging cases and for driving personalized treatment. In conclusion, the HIF-2α novel markers identified in this study might improve patients risk stratification and could be also used as putative drug targets being immunotherapy is one of the most promising anticancer treatment.